Should You Buy Esperion Therapeutics Inc (ESPR) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
Buy (long-term, beginner-friendly approach: start/scale in now). ESPR is showing an improving technical setup (MACD turning up, price pushing above the first resistance zone), strongly bullish options positioning (very low put/call ratios), and a meaningful growth inflection in the latest quarter (2025/Q3 revenue +69% YoY). Wall Street coverage is newly constructive with an Overweight and a $9 target, implying large upside from ~$3.46–$3.47. With no negative news flow in the past week and earnings coming 2026-02-25 (pre-market), the risk/reward favors initiating a position now rather than waiting.
Technical Analysis
Trend/Momentum: Mild bullish turn. The MACD histogram is positive (0.00242) and expanding, suggesting momentum is improving. RSI(6) at ~62.9 is neutral-to-bullish (not overbought). Moving averages are converging, often seen near a trend transition point.
Key levels: Pivot 3.187. Support S1 2.935 (then S2 2.779). Resistance R1 3.439 has effectively been tested/cleared with price ~3.46–3.47; next resistance R2 3.595 is the near-term upside reference.
Pattern-based forward bias: Similar-pattern stats point to modest upside next day/week (+0.4% / +1.07%) but softness over a month (-1.8%), which fits a choppy climb rather than a straight-line rally.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.